Join
Live feed
·
PRReleasevia Quantisnow
Harpoon Therapeutics Inc. logo

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

ByQuantisnow·Wall Street's wire, on your screen.
HARP· Harpoon Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HARP (Harpoon Therapeutics Inc.) and more on Quantisnow.